Incidence of adverse reactions in HIV patients treated with protease inhibitors : A Cohort Study

Incidence of adverse reactions in HIV patients treated with protease inhibitors : A Cohort Study

To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment. Ritonavir is the drug associated with the largest number of reactions, which appear during the first few mo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of acquired immune deficiency syndromes (1999) 2000-03, Vol.23 (3), p.236-245
Hauptverfasser: BONFANTI, P, VALSECCHI, L, DI CINTIO, E, MARTINELLI, C, FAGGION, I, LANDONIO, S, QUIRINO, T, PARAZZINI, F, CARRADORI, S, PUSTERLA, L, FORTUNA, P, TIMILLERO, L, ALESSI, F, GHISELLI, G, GABBUTI, A
Format: Artikel
Sprache:eng
Schlagworte:
Acquired immune deficiency syndrome
AIDS
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Drug therapy
HIV
Human immunodeficiency virus
Italy
Medical sciences
nelfinavir
Pharmacology. Drug treatments
proteinase inhibitors
saquinavir
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment. Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment.
ISSN:1525-4135
1944-7884
DOI:10.1097/00042560-200003010-00004